Description
VICTOZA is a high-performance GLP-1 receptor agonist containing Liraglutide. Manufactured by Novo Nordisk, it is a once-daily injectable medication primarily indicated for the treatment of Type 2 Diabetes and the reduction of cardiovascular risk in adults with heart disease. Victoza works by mimicking the natural hormone GLP-1, which stimulates insulin secretion when blood sugar is high, slows gastric emptying to prevent glucose spikes, and signals the brain to reduce appetite. Beyond blood sugar control, it is clinically proven to lower the risk of major cardiovascular events such as heart attack and stroke, making it a cornerstone therapy for metabolic health.
